首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2075780

骨髓增生性腫瘤治療市場：依疾病、藥物類別、通路及地區分類

Myeloproliferative Neoplasms Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，骨髓增生性腫瘤 (MSN) 治療市場規模將達到 101.1 億美元，到 2033 年將達到 133.9 億美元。預計 2026 年至 2033 年的複合年成長率將達到 4.1%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	101.1億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.10%	2033年市場規模預測：	133.9億美元

骨髓增生性腫瘤是一組罕見的骨髓疾病，會導致血球數量增加。骨髓增生性腫瘤的症狀包括頻繁頭痛、疲勞、瘀傷和異常出血、視力問題（如視力模糊和耳鳴）以及易感染疾病。此外，血液檢查是診斷骨髓增生性腫瘤的常用方法。這些檢查可以檢測血球數量，並能發現基因突變。其他檢查，例如骨髓檢查和腹部超音波，也需要進行。

骨髓中形成的血球類型因骨髓增生性疾病的類型而異。骨髓是骨骼內部的軟組織，也是血球的生成場所。骨髓增生性疾病包括多種類型，例如以下幾種：

慢性骨髓性白血病（CML）。
真性紅血球增多症。
原發性血小板增多症。
原發性纖維化。

市場動態

骨髓增生性腫瘤（MMO）治療產業的領導者正致力於研發創新療法。因此，預計市場研發活動的增加將推動全球MMO治療市場在預測期內的成長。例如，2023年2月23日，PharmaEssentia USA Corporation（PharmaEssentia Corporation的子公司）宣布，其洛培干擾素α-2b-njft（一種創新型單聚乙二醇化長效干擾素）已開始在成人原發性血小板增多症（ET）患者中開展IIb期臨床試驗，並已開始對首例患者進行給藥。 BESREMi（洛培干擾素α-2b-njft）是一種創新的單聚乙二醇化長效生技藥品。 PharmaEssentia Corporation是一家總部位於台灣的全球生物製藥創新企業，憑藉其深厚的專業知識和成熟的科學原理，在血液學和腫瘤學領域提供新型干擾素。由於採用了獨特的聚乙二醇化技術，BESREMi 可在體內長期發揮作用，設計為每兩週給藥一次（如果血液學穩定性已維持至少一年，則每四周給藥一次），從而可以靈活調整劑量，以滿足每位患者的個體需求。

本研究的主要特點：

本報告對全球骨髓增生性腫瘤（MMP）治療市場進行了詳細分析，預測了2026年至2033年（以2025年為基準年）的市場規模和複合年成長率（CAGR）。報告也指出了各細分市場的潛在商機，並說明了該市場極具吸引力的投資提案。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球骨髓增生性腫瘤治療市場的主要參與者：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球骨髓增生性腫瘤治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球骨髓增生性腫瘤治療市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Novartis AG
- PharmaEssentia Corporation
- Bristol Myers Squibb
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Incyte
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche AG
- Gamida Cell
- Sierra Oncology, Inc
- CTI BioPharma Corp
- Imago BioSciences
- AbbVie Inc
- Constellation Pharmaceuticals

第9章

參考
調查方法

簡介目錄

Product Code: CMI930

Myeloproliferative Neoplasms Treatment Market is estimated to be valued at USD 10.11 Bn in 2026 and is expected to reach USD 13.39 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 10.11 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.10%	2033 Value Projection:	USD 13.39 Bn

Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. The symptoms associated with Myeloproliferative Neoplasms include frequent headaches, tiredness, bruising or unusual bleeding, problem with eyes - such as blurred vision, ringing in the ears, getting more infectious than usual. Moreover, the diagnosis involves blood test to diagnose myeloproliferative neoplasms, the blood tests show the number of blood cells, and can look for genetic mutations. Also, there are other test which done like a bone marrow test, an ultrasound of abdomen.

Different myeloproliferative disorders affect different blood cells that form in the bone marrow. The bone marrow is the soft inner part of bones that makes the blood cells. There are number of different types of myeloproliferative disorders exist, which are;

Chronic myeloid leukaemia (CML)
Polycythaemia vera
Essential thrombocythaemia
Primary myelofibrosis

Market Dynamics

The key players in the myeloproliferative neoplasm treatment industry are focusing on research and development to develop innovative treatment for myeloproliferative neoplasm. Thus, an increase in research and developement activities in the market is expected to drive the global myeloproliferative neoplasms treatement market growth over the forecast period. For instance, on February 23, 2023, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the first patient is now being dosed in a phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET). BESREMi (ropeginterferon alfa-2b-njft) is innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients.

Key features of the study:

This report provides an in-depth analysis of the global myeloproliferative neoplasms treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2026-2033, considering 2025 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global myeloproliferative neoplasms treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global myeloproliferative neoplasms treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myeloproliferative neoplasms treatment

Detailed Segmentation:

Global Myeloproliferative Neoplasms Treatment Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
Essential Thrombocythemia (ET)
Myelofibrosis (MF)
Polycythemia Vera (PV)
Global Myeloproliferative Neoplasms Treatment Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
Tyrosine Kinase Inhibitors
Janus kinase inhibitors (JAKi)
Antimetabolites
Others (alkylating agents, etc.)
Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Novartis AG
Pharma
Essentia Corporation
Bristol Myers Squibb
Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Incyte
Johnson & Johnson
Teva Pharmaceutical Industries Ltd,
F. Hoffmann-La Roche AG
Gamida Cell
Sierra Oncology, Inc
CTI BioPharma Corp
Imago BioSciences
AbbVie Inc
Constellation Pharmaceuticals

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Myeloproliferative Neoplasms Treatment Market, By Disease Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Essential Thrombocythemia (ET)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Myelofibrosis (MF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Polycythemia Vera (PV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Myeloproliferative Neoplasms Treatment Market, By Drug Class, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Tyrosine Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Janus Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Myeloproliferative Neoplasms Treatment Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Region/Country, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- PharmaEssentia Corporation
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol Myers Squibb
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Incyte
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Johnson & Johnson
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Gamida Cell
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sierra Oncology, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CTI BioPharma Corp
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Imago BioSciences
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Constellation Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies